DermTech Adds Approximately 13 Million Covered Lives for the Foundational Assay of Its DermTech Melanoma Test (DMT)

(marketscreener.com) DermTech, Inc. , a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced favorable coverage policies from four commercial payers including Blue Cross Blue Shield of North Carolina , Blue Cross Blue Shield of South Carolina , Blue Cross Blue Shield of Louisiana and Blue Cross Blue Shield of Kansas City...https://www.marketscreener.com/quote/stock/DERMTECH-INC-64823450/news/DermTech-Adds-Approximately-13-Million-Covered-Lives-for-the-Foundational-Assay-of-Its-DermTech-Mela-42665980/?utm_medium=RSS&utm_content=20230105